ORIGINAL ARTICLE
No differences in miRNA expression in the stroma of ERG+ and ERG– prostate cancers
1
Center for Medical Genomics OMICRON, Jagiellonian University Medical College, Kraków, Poland
2
Department of Urology, Jagiellonian University Medical College, Kraków, Poland
3
Department of Pathomorphology, Jagiellonian University Medical College, Kraków, Poland
4
Department of Pathomorphology, University Hospital in Kraków, Kraków, Poland
5
Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
Submission date: 2023-09-25
Acceptance date: 2023-09-25
Publication date: 2024-01-17
Corresponding author
Krzysztof Okoń
Krzysztof Okoń, MD, PhD Department of Pathomorphology Jagiellonian University, Collegium Medicum 16 Grzegórzecka St., 31-531 Kraków, Poland
Krzysztof Okoń, MD, PhD Department of Pathomorphology Jagiellonian University, Collegium Medicum 16 Grzegórzecka St., 31-531 Kraków, Poland
Pol J Pathol 2023;74(4):265-270
KEYWORDS
TOPICS
ABSTRACT
Prostate cancer (PC) is one of the most common cancers in males. A significant proportion of PCs bear TMPRSS2-ETS translocation and overexpress ERG transcription factor, allowing classification into ERG+ and ERG– groups, which differ in several features including the tumor microenvironment. The aim of the study was to verify whether they differ in expression of the miRNA in the microenvironment. The material consisted of 150 radical prostatectomies. Immunohistochemistry (IHC) for ERG was done using a routine method. FISH for TMPRSS2-ETS translocation was done with a ZytoLight SPEC ERG/TMPRSS2 TriCheck Probe. From each case, a representative section was selected, and tumor and non-tumor were microdissected with the LMD7000 device. RNA was isolated using the RNeasy Mini Kit system (Qiagen) and miRNA libraries were prepared with the NEBNext Multiplex Small RNA Library Prep Set for Illumina and their sequencing was performed on the NexSeq 500. Statistical analysis was done with Statistica and R software. When analyzing the expression of miRNAs some differences could be seen, but after correction for multiple comparisons was applied, these were found to be non- significant.
REFERENCES (35)
1.
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021, 71: 209-249.
2.
Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310: 644-648.
3.
Wang J, Cai Y, Yu W, et al. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008, 68: 8516-8524.
4.
Carver BS, Tran J, Chen Z, et al. ETS rearrangements and prostate cancer initiation. Nature 2009, 457: E1; discussion E2-3.
5.
Yu J, Yu J, Mani RS, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010, 17: 443-454.
6.
Font-Tello A, Juanpere N, de Muga S, et al. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. Prostate 2015; 75: 1216-1226.
7.
Kaczmarczyk-Sekula K, Galazka K, Glajcar A, et al. Prostate cancer with different ERG status may show different FOXP3- positive cell numbers. Pol J Pathol 2016; 67: 313-317.
8.
Milek K, Kaczmarczyk-Sekula K, Strzepek A, et al. Mast cells influence neoangiogenesis in prostatic cancer independently of ERG status. Pol J Pathol 2016; 67: 244-249.
9.
Milek K, Szpor J, Tyrak KE, et al. Lymphoid infiltrate and ERG status in prostatic carcinoma. Analytical and Quantitative Cytopathology and Histopathology 2018; 40: 183-192.
10.
Strzepek A, Kaczmarczyk K, Bialas M, et al. ERG positive prostatic cancer may show a more angiogenetic phenotype. Pathol Res Pract 2014; 210: 897-900.
11.
Cozar JM, Robles-Fernandez I, Rodriguez-Martinez A, et al. The role of miRNAs as biomarkers in prostate cancer. Mutat Res Rev Mutat Res 2019; 781: 165-174.
12.
Abramovic I, Ulamec M, Katusic AB, et al. miRNA in prostate cancer: challenges toward translation. Epigenomics 2020; 12: 543-558.
13.
Fine SW, Amin MB, Berney DM, et al. A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. Eur Urol 2012; 62: 20-39.
14.
Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016; 40: 244-252.
15.
Kaczmarczyk K, Dyduch G, Bialas M, et al. Frequency of ERG- positive prostate carcinoma in Poland. Pol J Pathol 2013; 64: 175-179.
16.
Griffiths-Jones S, Grocock RJ, van Dongen S, et al. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006, 34: D140-144.
17.
Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26: 139-140.
18.
Pietrus M, Seweryn M, Kapusta P, Wołkow P, Pityński K, Wątor G. Low expression of miR-375 and miR-190b differentiates grade 3 patients with endometrial cancer. Biomolecules 2021, 11: 274. DOI: 10.3390/biom11020274.
19.
R Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2017.
20.
Steele CB, Li J, Huang B, et al. Prostate cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer 2017; 123 Suppl 24: 5160-5177.
21.
Harryman WL, Warfel NA, Nagle RB, et al. The tumor microenvironments of lethal prostate cancer. Adv Exp Med Biol 2019; 1210: 149-170.
22.
Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech 2021, 14: dmm047662. DOI: 10.1242/dmm.047662.
23.
Sharma N, Baruah MM. The microRNA signatures: aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol 2019; 21: 126-144.
24.
Altschuler J, Stockert JA, Kyprianou N. Non-coding RNAs set a new phenotypic frontier in prostate cancer metastasis and resistance. Int J Mol Sci 2021, 22: 2100. DOI: 10.3390/ijms22042100.
25.
Wood SL, Brown JE. Personal medicine and bone metastases: biomarkers, micro-RNAs and bone metastases. Cancers (Basel) 2020, 12: 2109. DOI: 10.3390/cancers12082109.
26.
Shan G, Gu J, Zhou D, et al. Cancer-associated fibroblast- secreted exosomal miR-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF- signaling pathway. Exp Mol Med 2020, 52: 1809-1822.
27.
Zhang T, Wang Y, Dong Y, et al. Identification of novel diagnostic biomarkers in prostate adenocarcinoma based on the stromal-immune score and analysis of the WGCNA and ceRNA network. Dis Markers 2022, 2022: 1909196. DOI: 10.1155/ 2022/1909196.
28.
Xie T, Fu DJ, Li ZM, et al. CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling. Mol Cancer 2022; 21: 173. DOI: 10.1186/ s12943-022-01630-9.
29.
Shan L, Ji T, Su X, et al. TMPRSS2-ERG fusion promotes recruitment of regulatory T cells and tumor growth in prostate cancer. Am J Med Sci 2018; 356: 72-78.
30.
Kaur HB, Guedes LB, Lu J, et al. Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol 2018; 31: 1539-1552.
31.
Fayyaz S, Farooqi AA. miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells. Immunogenetics 2013; 65: 315-332.
32.
Kao CJ, Martiniez A, Shi XB, et al. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene 2014; 33: 2495-2503.
33.
Todorova K, Metodiev MV, Metodieva G, et al. Micro-RNA- 204 participates in TMPRSS2/ERG regulation and androgen receptor reprogramming in prostate cancer. Horm Cancer 2017; 8: 28-48.
34.
Zhang Z, Lanz RB, Xiao LJ, et al. The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. Oncotarget 2016; 7: 37993-38003.
35.
Kim J, Wu L, Zhao JC, et al. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene 2014, 33: 5183-5192.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
